Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers
Hidenori Toyoda(Ogaki Municipal Hospital), Takashi Matsunaga(Shiga University of Medical Science), Takashi Kumada(Gifu Kyoritsu University), Masatoshi Kudo(Kindai University), Fumihiro Urano(Toyohashi Municipal Hospital), Yukio Osaki(Osaka Red Cross Hospital), Hiroko Oka(Osaka City General Hospital)
Cited by 127
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k